Skip to content

Press Release · Press Releases

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer

Issued by PR Newswire

Image: PR Newswire

Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & Johnson was granted accelerated approval from the U.S. Food and Drug...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories

Press Release

IMAGECARE TEAMSTERS IN NEW JERSEY AUTHORIZE STRIKE

Health Care Workers Prepare to Hit Picket Line to Win First Union Contract WAYNE, N.J., Nov. 6, 2026 /PRNewswire/ -- Members of Teamsters Local 125 at ImageCare in Sussex County have voted to authorize a strike as they continue fighting for their first union contract. The 45 technologists...

PR Newswire ·

Press Release

Tech employment gains momentum in October, CompTIA analysis finds

Tech industry adds 7,200 jobs and IT occupations gain 26,000 as job postings and AI skills demand rise DOWNERS GROVE, Ill., Nov. 6, 2026 /PRNewswire/ -- Technology employment and employer demand for tech talent strengthened in October, with gains in industry and occupation employment and...

PR Newswire ·